TL;DR: The Centers for Medicare & Medicaid Services modified NCD 90 covering serum iron studies, effective March 7, 2026. Here's what billing teams need to know.
This update to the CMS serum iron studies coverage policy clarifies medical necessity criteria for ferritin, serum iron, total iron binding capacity (TIBC), and transferrin testing. NCD 90 in the Medicare system governs when these diagnostic lab tests are covered — and the policy details matter because inappropriate or underdocumented orders for iron studies are a consistent claim denial trigger. No specific CPT codes are listed in the policy document, but the clinical criteria driving coverage decisions affect every lab billing team ordering these panels.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Serum Iron Studies |
| Policy Code | NCD 90 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Clinical laboratory, internal medicine, gastroenterology, hematology, nephrology, oncology, primary care |
| Key Action | Review medical necessity documentation for all iron study orders against the updated NCD 90 criteria before billing March 7, 2026 and beyond |
CMS Serum Iron Studies Coverage Criteria and Medical Necessity Requirements 2026
NCD 90 is the National Coverage Determination governing Medicare coverage of serum iron studies — specifically ferritin, serum iron, TIBC, and transferrin. The coverage policy draws a clear line: these tests are covered when ordered to evaluate disorders of iron metabolism, primarily iron deficiency and iron overload. Ordering them without documented clinical justification tied to one of the recognized indications will get your claim denied.
The medical necessity standard under this coverage policy is indication-based. CMS breaks the coverage criteria into two major buckets: iron deficiency evaluation and iron overload evaluation. Each has a concrete list of supporting presentations.
For iron deficiency, covered clinical presentations include:
| # | Covered Indication |
|---|---|
| 1 | Decreased mean corpuscular volume (MCV) |
| 2 | Decreased hemoglobin or hematocrit with low or normal MCV |
| 3 | Increased red cell distribution width (RDW) with low or normal MCV |
| 4 | Pica (abnormal appetite) |
| 5 | Acute or chronic gastrointestinal blood loss |
| 6 | Hematuria |
| 7 | Menorrhagia |
| 8 | Malabsorption |
| 9 | Status post-gastrectomy or status post-gastrojejunostomy |
| 10 | Malnutrition |
| 11 | Preoperative autologous blood collection |
| 12 | Malignant, chronic inflammatory, or infectious conditions associated with anemia |
| 13 | Significant surgical blood loss without adequate iron replacement |
Each of these is a legitimate pathway to a covered claim. But the documentation in the chart has to connect the dots — an order with no matching diagnosis or clinical presentation is the pattern that generates a claim denial.
For iron overload, CMS recognizes a separate set of presentations that support medical necessity:
| # | Covered Indication |
|---|---|
| 1 | Chronic hepatitis |
| 2 | Diabetes |
| 3 | Hyperpigmentation of skin |
| 4 | Arthropathy |
| 5 | Cirrhosis |
| 6 | Hypogonadism |
| 7 | Hypopituitarism |
| 8 | Impaired porphyrin metabolism |
| 9 | Heart failure |
| 10 | Multiple transfusions |
| 11 | Sideroblastic anemia |
| 12 | Thalassemia major |
| 13 | Cardiomyopathy, cardiac dysrhythmias, and conduction abnormalities |
For iron overload specifically, ferritin is valuable for both initiating and monitoring treatment. That monitoring indication is worth noting — it gives you a documented basis for repeat testing when a patient is being treated for hemochromatosis or hemosiderosis.
A note on timing and test conditions: CMS specifically states iron studies are best performed when the patient is fasting in the morning and has abstained from medications that may influence iron balance. This is clinical context, not just a billing footnote. If your ordering providers aren't flagging medication status and fasting status in their documentation, the interpretation section of the claim gets thin fast.
The policy does not mention prior authorization for serum iron studies. These are diagnostic lab tests under the Medicare benefit category. But lack of prior authorization requirements doesn't mean lack of scrutiny — medical necessity documentation is your primary audit exposure here.
CMS Serum Iron Studies Exclusions and Non-Covered Indications
The CMS serum iron studies coverage policy does not publish an explicit exclusion list in the same way some NCDs do. But the structure of the policy creates implicit non-coverage situations you need to watch.
Testing outside the two recognized indication buckets — iron deficiency evaluation and iron overload evaluation — is where you're at risk. A serum iron panel ordered as part of a routine annual workup with no documented abnormality or clinical indication doesn't meet the medical necessity standard.
The policy also flags an interpretation challenge that matters for repeat testing. Ferritin and iron/TIBC (or transferrin) are acute phase reactants. In patients with acute or chronic inflammatory conditions, infection, or tissue injury from surgery, trauma, or necrosis, these values are harder to interpret. CMS acknowledges this complexity — but that doesn't mean repeated testing in an inflammatory context is automatically covered. Your documentation needs to show why the repeat test was clinically necessary given the confounding factors.
High-dose supplemental iron can elevate serum iron artificially. Oral contraceptive use and pregnancy elevate TIBC and transferrin. If these factors are present and the provider ordered testing, the medical record needs to explain the clinical rationale. Absent that context, a reviewer can reasonably question whether the test was necessary at that time.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Iron deficiency evaluation — abnormal CBC values (low MCV, low Hgb/Hct, elevated RDW) | Covered | Not specified in NCD 90 | Document specific CBC abnormality in the order |
| Pica (abnormal appetite) | Covered | Not specified in NCD 90 | Must be documented in the clinical record |
| Acute or chronic GI blood loss | Covered | Not specified in NCD 90 | Diagnosis must be active and documented |
| Hematuria | Covered | Not specified in NCD 90 | Link iron studies to anemia workup in documentation |
| Menorrhagia | Covered | Not specified in NCD 90 | Connect to iron deficiency clinical presentation |
| Malabsorption | Covered | Not specified in NCD 90 | Documented malabsorption condition required |
| Status post-gastrectomy or gastrojejunostomy | Covered | Not specified in NCD 90 | Post-surgical status must be in the record |
| Malnutrition | Covered | Not specified in NCD 90 | Document nutritional deficiency diagnosis |
| Preoperative autologous blood collection | Covered | Not specified in NCD 90 | Tie to presurgical planning documentation |
| Anemia with malignant, chronic inflammatory, or infectious conditions | Covered | Not specified in NCD 90 | Differentiation from iron deficiency anemia is the clinical goal — document it |
| Post-surgical blood loss without adequate iron replacement | Covered | Not specified in NCD 90 | Months to years post-surgery may qualify — document timeline |
| Iron overload evaluation — hemochromatosis | Covered | Not specified in NCD 90 | Ferritin useful for initiating and monitoring treatment |
| Iron overload evaluation — hemosiderosis | Covered | Not specified in NCD 90 | Elevated iron, normal/low TIBC, elevated saturation pattern |
| Iron overload — clinical presentations (cirrhosis, cardiomyopathy, multiple transfusions, thalassemia major, sideroblastic anemia, etc.) | Covered | Not specified in NCD 90 | Each presentation must be documented as the clinical reason for testing |
| Routine annual workup without documented indication | Not Covered | Not specified in NCD 90 | No recognized clinical indication = no medical necessity |
| Testing during acute inflammation without clinical rationale for timing | At risk for denial | Not specified in NCD 90 | Confounding factors must be addressed in documentation |
CMS Serum Iron Studies Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 is your line in the sand. Claims for serum iron studies billed after that date will be evaluated against the modified NCD 90 criteria. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Audit your current order templates for serum iron studies. Check that ordering providers are required to document a specific clinical indication tied to one of the two coverage buckets — iron deficiency evaluation or iron overload evaluation. Generic "anemia workup" without further specificity is not enough. |
| 2 | Update your charge capture and documentation checklists before March 7, 2026. Every iron study claim should have a corresponding diagnosis entry in the medical record that maps to a recognized NCD 90 indication. If your EHR order set doesn't prompt for this, flag it to your clinical informatics team now. |
| 3 | Flag iron overload monitoring claims separately. Ferritin is explicitly recognized as useful for monitoring hemochromatosis and hemosiderosis treatment. If your providers are ordering repeat ferritin for active treatment monitoring, make sure "monitoring treatment for iron overload" is documented — not just the underlying diagnosis. |
| 4 | Address the acute phase reactant problem in your documentation protocols. Patients with inflammatory conditions, active infection, or recent surgery present an interpretation challenge that CMS explicitly recognizes. When iron studies are ordered in these contexts, the provider's documentation should explain why testing was clinically necessary despite the confounding factors. Train your providers on this. A missing explanation is a preventable denial. |
| 5 | Check fasting and medication status documentation. CMS states iron studies are best performed fasting in the morning with medications that influence iron balance held. If your ordering workflow doesn't capture this, a reviewer can question whether the result — and thus the test — was clinically valid. Add a documentation prompt for fasting status and relevant medications. |
| 6 | Review your denial patterns now. Pull serum iron study denials from the last 12 months. If you're seeing medical necessity denials, look at whether the documented indications match the NCD 90 criteria. That pattern will predict your post-March 7 exposure. If your denial rate is already elevated on these codes, talk to your compliance officer before the effective date. |
| 7 | Confirm your MAC's local policies. NCD 90 is a national coverage determination, but your Medicare Administrative Contractor may have issued a local coverage determination (LCD) or billing guidance that sits alongside or supplements the NCD. Check with your MAC directly — some contractors have additional documentation requirements for lab testing that go beyond what the NCD specifies. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Serum Iron Studies Under NCD 90
The NCD 90 policy document does not list specific CPT, HCPCS, or ICD-10 codes. This is a known limitation of this particular NCD — it governs coverage criteria without enumerating the codes to which it applies.
For serum iron studies billing, your coding team should verify the applicable CPT codes through your MAC's associated LCD (if one exists), your laboratory's current charge master, and the AMA CPT codebook for the current year. Common codes associated with iron studies panels — including ferritin assays, serum iron, TIBC, and transferrin — should be validated against the NCD 90 criteria on a per-claim basis.
Do not assume a code is covered because it's in your charge master. The coverage determination is criteria-based, not code-based. Every claim lives or dies on the documented clinical indication.
If you need code-level guidance for serum iron studies billing under Medicare, your MAC is the authoritative source. Reach out directly or check their website for any associated LCD or billing article that references NCD 90.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.